Hemanext had a major presence at the 2017 AABB Annual Meeting where we showcased our Hemanext RBC Processing System and Microvascular Analyzer (MVA) technology, our proprietary solution for assessing deformability of stored red blood cells.
We are proud to announce the acceptance and presentation of “Oxygen Content – Uncontrolled and Overlooked Parameter Associated with Stored Red Cell Concentrate: Unexpectedly Wide Distribution” abstract and poster at the recent International Society of
Annual Shareholder Meeting to be held May 5, 2017. Details posted in Investor Portal in 04-18-2017 Shareholder Letter.
Wide Distribution of Initial Oxygen Saturation Levels in Red Cells Stored for Transfusion, May Significantly Influence Cell Quality and Therapeutic Efficacy
Bethesda, MD – March 6, 2017 – New Health Sciences, Inc. (NHSi), a medical technology company focused on improving transfusion therapy, is happy to announce the completion and recent publication of their study exploring the
New Health Sciences has closed an additional $6.0 million Series B financing raised from existing private investors. NHSi will use the new capital to fund continued development of its Hemanext technology and to support an
Recently, Dr. Tatsuro Yoshida, the Director of Research for New Health Sciences, Inc. was invited to speak in Italy at a conference organized by Centro Nazionale Sangue, of the Istituto Superiore Di Sanita, Centro Nazionale
Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells
The July issue of Blood includes an article published by New Health Sciences and collaborators at the University of Colorado describing the fundamental science behind the irreversible damage caused to red cells by oxygen during
Bethesda, MD – June 21, 2016 – New Health Sciences, Inc. (NHSi), a medical technology company focused on innovations to improve transfusion therapy, announced the successful completion of a National Institute of Health (NIH), National